Press Releases
May 16, 2022
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights
May 9, 2022
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
May 3, 2022
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
May 2, 2022
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
April 20, 2022
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
April 13, 2022
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
April 13, 2022
HOOKIPA to Participate in the Kempen Life Sciences Conference
March 24, 2022
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
March 22, 2022
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
March 17, 2022
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
March 8, 2022
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
March 2, 2022
HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
March 1, 2022
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
February 15, 2022
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV
February 9, 2022
HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
January 18, 2022
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
January 4, 2022
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference